Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	09/964,065
-INFORMATION DISCLOSURE	Filing Date	September 26, 2001
P STAXEMENT BY APPLICANT	First Named Inventor	KOVESDI, Imre
7	Group Art Unit	KOVESDI, Imre RECEIVED
EB 1 9 2002 (Life as many sheets as necessary)	Examiner Name	FFR 2 2 2002
Shoot S 1 lot 2	Attorney Docket Number	212257

WY & TRAC	ENE	_ 1 ,,,,,				TE(CH CENT	FR 1600/2000		
(U.S. PATENT DOCUMENTS									
		U.S. Patent Docum					1.			
Examiner Initials ¹	Cite No.	Patent Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate		
50°	AA	4,405,712		Vande Woude	09-20-1983	435	5			
STP	AB	5,700,470		Saito et al.	12-23-1997	424	233.1			
50P	AC	5,851,106		Kovesdi et al.	12-22-1998					
50P	AD	5,994,106		Kovesdi et al.	11-30-199 9					
508	ΑE	6 ,127,175		Vigne et al.	10-03-2000					

					FOREIGN PATENT DOCUMENTS	<u> </u>				
Examiner	Cite	<u> </u>	Foreign Patent Documen	t I Kind	Name of Patentee or Applicant of Cited	Name of Patentee or Applicant of Cited Date of Publication of Cited		ļ	Trans	slation 1
Initials ¹	No.	Office	Number	Code	Document Document	Document MM-DD-YYYY	Class	Subclass	Yes	No*
50P	AF	AU	94/68503	Α	Transgene S.A.	12-08-1994	•			_
900	AG	AU	94/72646	Α	Rhône-Poulenc Rorer	01-26-1995				
55P	AH	CA	2,117,668	A	Sumitomo Pharm. Co.	09-10-1995				
SOP	ΑI	FR	2707664	Α	CNRS (Paris)	01-20-1995	T		Х	
SOP	AJ	wo	94/08026	Α	Rhône-Poulenc Rorer	04-14-1994				
508	AK	wo	94/11506	Α	ARCH Devel. Corp.	05-26-1994				
Sor	AL	wo	94/12649	Α	Genzyme Corp.	06-09-1994				
SDP	AM	wo	94/28152	Α	Transgene S.A.	12-08-1994		·	Χ -	\prec
50P	AN	wo	94/28938	Α	University of Michigan	12-22-1994				
SOP	AO	wo	95/00655	A	McMaster University	01-05-1995				
SDP	ΑP	wo	95/26411	Α	UAB Research Found.	10-05-1995				
50P	AQ	wo	95/27071	Α	University of Texas	10-12-1995				
SOP	AR	wo	96/14061	Α	Cell Genesys, Inc.	05-17-1996				


* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.	Scott D. Pnih	Date Considered	8/12/02	
---------------------	---------------	--------------------	---------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.







Please type a plus sign (+) inside this box

PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	09/964,065
OT INFORMATION DISCLOSURE	Filing Date	September 26, 2001
STATEMENT BY APPLICANT	First Named Inventor	KOVESDI, Imre
 \	Group Art Unit	1636 /632
FEB 1 9 2002 (Use as many sheets as necessary)	Examiner Name	
Sheet 2 of 2	Attorney Docket Number	213257

on PTO-892


V		2 21323,							
THAD	EMPR								
		OTHER - NON PATENT LITERATURE DOCUMENTS		-4:					
Examiner Initials¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	ransla s	No*					
508	AS	ARMENTANO et al., Hum. Gene Ther., 6, 1343-1353 (October 1995).	\perp						
506	AT	BARR et al., Gene Ther., 1, 51-58 (1994).							
508	AU	BERKNER et al., Nucl. Acids Res., 11 (17), 6003-6020 (September 1983).							
SDP	A۷	BERKNER, BioTechniques, 6 (7), 616-629 (July/August 1988).							
SDP	AW	BOUCHER et al., Hum. Gene Ther., 5, 615-639 (1994).							
SDP	AX	BROUGH et al., Virology, 190 (2), 624-634 (October 1992).							
50°	AY	BROUGH et al., Virology, 196 (1), 269-281 (1993).							
	AZ-	BRUNET et al., Mol. Cell. Biol., 8 (11), 4799-4807 (November 1988).							
SOP	ВА	CRYSTAL et al., Nature Med., 1 (1), 15-17 (1995).							
Spp	ВВ	DAVIDSON et al., J. Virol., 61 (4), 1226-1239 (April 1987).							
500	ВС	DeMATTEO et al., Transplantation 63 (2), 315-319 (1997).							
SOP	BD	ENGELHARDT et al., PNAS USA, 91 (13), 6196-6200 (June 1994).	\perp						
500	BE	ENGLEHARDT et al., Hum. Gene Ther., 4 (6), 759-769 (December1993).							
SDP	BF	FALLAUX et al., Hum. Gene Ther., 7, 215-222 (January 20, 1996).							
30°	BG	FRIEDMANN et al., Scientific American, 96-101 (June 1997).							
SDP	ВН	GILARDI et al., FEBS Lett., 267 (1), 60-62 (July 1990).							
SDP	BI	GRAHAM et al., J. Gen. Virol., 36 (1), 59-74 (July 1977).							
	₽J	GRODZICKER et al., Cell, 21 (2), 453-463 (September 1980).	3RODZICKER et al., Cell, 21 (2), 453-463 (September 1980). 70 COPT						
50P	BK	IMLER et al., Gene Ther., 3, 75-84 (1996).							
508	BL	KLESSIG et al., Mol. Cell Biol., 4 (7), 1354-1362 (July 1984).							
508	ВМ	KREEGER, "Hot Papers: Gene Therapy," The Scientist, 10 (4) (February 19, 1996).							
508	BN	KROUGLIAK et al., Hum. Gene Ther., 6, 1575-1586 (December 1995).							

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).


⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examine SigNat.	Swott D Priche	Date Considered 8//z/0Z

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



on Pro-892/



PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				Complete if Known	
	Substitute for form 1449A/B/PTO		Application Number	09/964,065	
,	TP INFORMATION D	DISCLOSURE	Filing Date	September 26, 2001	
STÂTEMENT BY APPLICANT			First Named Inventor	KOVESDI, Imre	
	1 0 2002		Group Art Unit	1636 1632	
	LB 1 3 1001 (Use as many sheets	as necessary)	Examiner Name		
Z,	Sheet 3	of 3	Attorney Docket Number	213257	
`	CONTRACTOR OF THE PARTY OF THE		<u> </u>		

		OTHER - NON PATENT LITERATURE DOCUMENTS	Trans	slation
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No [*]
SDP	В0	LEMARCHAND et al., PNAS USA, 89 (14), 6482-6486 (July 15, 1992).		
SDF	ВР	MASTRANGELI et al., J. Clin. Invest., 91 (1), 225-234 (January 1993).		
SDP	BQ	MITTEREDER et al., Hum. Gene Ther., 5 (6), 771-729 (June 1994).		
SOP	BR	MORIN et al., Mol. Cell Biol., 9 (10), 4372-4380 (October 1989).		
SOP	BS	ORKIN et al., Report and Recommendations to the Panel to Assess NIH Investment in Research on Gene Ther. (1995).		
	BT	ROBERTS et al., J. Virol., 56 (2), 404-413 (November 1985). 7, 0 copy		
SDP	BU	ROSENFELD et al., Cell, 68 (1), 143-158 (January 10, 1992).		
SDP	BV	SCHAACK et al., J. Virol., 69, 4079-4085 (July 1995).		
50P	BW	SCHULICK et al., J. Clin. Invest., 99 (2), 209-219 (1997).		
SDP	вх	SIMON et al., Hum. Gene Ther., 4 (6), 771-780 (December 1993).		
SDP	BY	TRAPNELL et al., Curr. Opin. Biotechnol., 5, 617-625 (1994).		
50°	BZ	VERMA et al., Nature, 389, 239-242 (1997).		
SDP	CA	VOS et al., Virology, 172 (2), 634-642 (October 1989).		
5DP	СВ	WANG et al., Gene Ther., 2, 775-783 (1995).		
SDP	CC	WEINBERG et al., PNAS USA, 80 (17), 5383-86 (September 1983).		
5»P	CD	YANG et al., PNAS USA, 91 (10), 4407-4411 (May 1994).		
508	CE	YEH et al., J. Virol., 70 (1), 559-565 (January 1996).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.	Six D. Pricke	Date Considered	8/12/02
---------------------	---------------	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.